oa Angiotensin-converting enzyme inhibitor-induced angioedema may not be a class-related event

References

1. Reid M, Euerle B, Bollinger ME. Urticaria and Angioedema. eMedicine. 2008;
   [Google Scholar]
2. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. Arch Intern med. 1994; 154::513–523
   [Google Scholar]
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327::685–691
   [Google Scholar]
4. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006; 354::131–140
   [Google Scholar]
5. Alkharouf J, Nalinikumari K, Corry D, Tuck M. Long-term effects of the angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus. Am J Hypertens. 1993; 6::337–343
   [Google Scholar]
6. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med. 1995; 332::118–120
   [Google Scholar]
7. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin- converting enzyme inhibitors. Hypertension. 2008; 51::1624–1630
   [Google Scholar]
8. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Internal Med. 1992; 117::234–242
   [Google Scholar]
9. Mahoney EJ, Devaiah AK. Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk? Otolaryngol Head Neck Surg. 2008; 139::105–108
   [Google Scholar]
10. Sheffer AL, Austen KF, Rosen FS, Fearon DT. Acquired deficiency of the inhibitor of the first component of complement: report of five additional cases with commentary on the syndrome. J Allergy Clin Immunol. 1985; 75::640–646
    [Google Scholar]
11. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992; 71::206–215
    [Google Scholar]
12. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1-inhibitor. N Engl J Med. 1987; 316::1360–1366
    [Google Scholar]
13. Cugno M, Cicardi M, Coppola R, Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology. 1996; 33::361–364
    [Google Scholar]
14. Simmons BB, Folsom MA, Bryden LA, Studdiford JS. Angioedema after local trauma in a patient on angiotensin-converting enzyme inhibitor therapy. J Am Board Fam Med. 2008; 21::577–579
    [Google Scholar]
15. Marrocco-Trischitta MM, Melissano G, de Dominicis D, Chiesa R. Angiotensin- converting enzyme inhibitor- induced angioedema following carotid endarterectomy misdiagnosed as cervical hematoma. Ann Vasc Surg. 2006; 20::145–147
    [Google Scholar]
16. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angioedema. Lancet. 1998; 351::1693–1697
    [Google Scholar]
17. Kopp UC, Farley DM, Smith LA. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. Am J Physiol. 1997; 272::R2009–R2016
    [Google Scholar]
18. Sigler C, Annis K, Cooper H, Haber H, Van deCarr S. Examination of baseline levels of carboxypeptidase N and complement as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol. 1997; 133::972–975
    [Google Scholar]
19. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-edema on ACE inhibitors. Lancet. 2002; 359::2088–2089
    [Google Scholar]
20. Sulpizio AC, Pullen MA, Edwards RM, Brooks DP. The effect of acute angiotensin converting enzyme(ACE) and neutral endopeptidase 24.11(NEP) inhibition on plasma extravasation in the rat. J Pharmacol Exp Ther. 2004; 309::1141–1147
    [Google Scholar]
21. Lefebvre J, Murphy LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002; 39::460–464
    [Google Scholar]
22. Brown NJ, Snowden M, Griffin MR. Recurrent angioedema-converting enzyme inhibitor-associated angioedema. JAMA. 1997;278
    [Google Scholar]
23. Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002; 22::1173–1175
    [Google Scholar]
24. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern med. 2004; 164::910–913
    [Google Scholar]
25. Malde B, Regalado J, Greenberg PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007; 98::57–63
    [Google Scholar]
26. Gibbs CR, Lip GYH, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of african origin. Br J Clin Pharmacol. 1999; 48::861–865
    [Google Scholar]
27. Sarkar P, Grainne N, George H. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth. 2006; 53::994–1003
    [Google Scholar]